Through tailored products, adaptable service choices, and unwavering scientific support, Alpha Lifetech Inc. guarantees researchers access to the most efficient tools for targeted payload delivery.
Our team of experienced scientists works closely with customers to design and execute tailored strategies for nanobody discovery, ensuring high-quality leads for ADC programs.
Learn More
Comprehensive antibody humanization services from a broad range of parental species including llama, alpaca, mouse, rat, rabbit, and avian vectors.
Learn More
Our Membrane Proteomics platform offers comprehensive identification, expression, and characterization of challenging GPCRs and ion channel target proteins.
Learn More
Alpha Lifetech constructs native antibody libraries (scFv, Fab, VHH Formats and customized) from host animals like Llama, Alpaca, Camel, and Goat.
Learn MoreTraditional Antibody-Drug Conjugate (ADC) technology has transformed clinical oncology, yet full-length monoclonal antibodies (~150 kDa) face intrinsic limitations: poor tumor microenvironment penetration, slow blood clearance, off-target toxicity, and complex linker chemistry. Single-domain VHH antibodies (Nanobodies) derived from Alpacas (*Vicugna pacos*) offer a groundbreaking structural solution.
At approximately ~15 kDa, Alpaca Nanobodies are one-tenth the size of conventional IgG antibodies. Their minute hydrodynamic radius permits rapid extravasation from blood vessels into solid tumor tissues, penetrating dense extracellular matrices and reaching hypoperfused core regions that standard ADCs fail to access.
Featuring extended Complementarity-Determining Region 3 (CDR3) loops, alpaca VHH domains can bind hidden, recessed, or sterically hindered epitopes—such as active sites of cell-surface enzymes and GPCR clefts—that are topologically inaccessible to bulky monoclonal antibodies.
Nanobodies clear rapidly from non-target systemic circulation, minimizing systemic toxicity and neutropenia. Furthermore, engineered single-cysteine or enzymatic tags enable site-specific conjugation, achieving uniform Drug-to-Antibody Ratios (DAR = 1, 2, or 4) without compromising antigen binding stability.
The modular architecture of camelid single-domain antibodies unlocks therapeutic avenues previously deemed unattainable with conventional immunoglobulins. By leveraging Alpaca VHH domain targeting, biopharmaceutical researchers are developing advanced therapeutic vectors across high-unmet-need clinical indications:
The global ADC market is projected to surpass $20 billion by 2030, with a significant shift toward next-generation antibody fragments. Global pharmaceutical developers are increasingly channeling investments into Nanobody-Drug Conjugate (NDC) modalities. Alpaca nanobodies eliminate Fc-mediated off-target uptake by macrophages and immune cells, effectively expanding the therapeutic window for ultra-potent payloads like PBD dimers and topoisomerase I inhibitors.
Unlike standard full-length IgGs requiring complex mammalian expression systems (CHO cells) and intricate glycosylation monitoring, single-domain Alpaca VHH antibodies possess exceptional thermal stability and solubility. They can be economically expressed at ultra-high yields in microbial platforms such as Escherichia coli or Pichia pastoris, dramatically lowering biological Cost of Goods (COGS) for commercial production.
Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents. Whether you're working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech's comprehensive range of research products will help you achieve accurate and reliable results. We pride ourselves on being able to offer a comprehensive set of high-quality products and services tailored to customer needs, which help advance the projects of scientific research institutions, academics, and enterprises in the life science industry.
Our years of manufacturing experience and refined products provide you with better protection
Alpha Lifetech Inc. is committed to providing the highest level of customer services, competitive pricing, speedy delivery, and a comprehensive, cutting-edge product offering. Our sales and technical support staff are available to help you select the right products and service solutions. As a reliable supplier and partner, Alpha Lifetech Inc. always puts customers first. We cherish every opportunity to collaborate with worldwide customers in scientific exploration. Welcome to contact our technical support at any time.
"Exceptional Nanobody discovery capabilities from Alpha Lifetech. Their team's dedication to customer satisfaction and scientific excellence is evident in every interaction. Grateful for their partnership and looking forward to future collaborations!"
"Quality products! Our experience with Alpha Lifetech has been nothing short of outstanding."
"Simply put, Alpha Lifetech delivers. Their dedication to customer satisfaction and quality service is unmatched, and we're grateful to have them as a trusted partner."
Alpha Lifetech Inc. provides a wide range of technology platforms, including membrane protein, antibody discovery, single B cell sorting, hybridoma technology, and aptamer platforms tailored for therapeutic ADC and bioconjugate research.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies.
Explore Platform
The aptamer platform includes SELEX aptamer library synthesis, screening for targets (proteins, peptides, small molecules), and chemical optimization for targeted therapy and diagnostic biosensors.
Explore Platform
Our mAb development services combine phage display, single-B cell sorting, and classical hybridoma technologies to produce ultra-high affinity antibodies across diverse species.
Explore PlatformBrowse our core antibody discovery, screening, and development technical services supporting global biopharma innovation.
Custom alpaca and llama immunization, phage display library construction, and nanobody screening tailored for ADC targets.
View Details
High-throughput selection of antigen-binding fragments (Fab) for therapeutic, diagnostic, and structural biological studies.
View Details
Generation of stable, high-affinity single-chain variable fragments (scFv) engineered for CAR-T and ADC formatting.
View Details
Robust M13 and T7 phage display platforms for screening high-diversity peptide and antibody fragment libraries.
View Details
Construction of immune, native, or synthetic phage display libraries exceeding >109 independent clones.
View Details
Biopanning and high-throughput ELISA screening strategies for membrane targets, peptides, and recombinant antigens.
View Details
Rapid isolation of antigen-specific single B cells from immunized alpacas, mice, or human peripheral blood.
View Details
Classical high-yield hybridoma generation and subcloning platforms delivering robust monoclonal antibody lineages.
View Details